|Year : 2012 | Volume
| Issue : 2 | Page : 124-129
Development and evaluation of microporous osmotic tablets of diltiazem hydrochloride
Afifa Bathool, DV Gowda, Mohammed S Khan, Ayaz Ahmed, SL Vasudha, K Rohitash
Department of Pharmaceutics, JSS College of Pharmacy, JSS University, SS Nagar, Mysore, India
|Date of Web Publication||16-Jun-2012|
Department of Pharmaceutics, JSS College of Pharmacy, S S Nagara, Bannimantap, Mysore - 570 015, Karnataka
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Microporous osmotic tablet of diltiazem hydrochloride was developed for colon targeting. These prepared microporous osmotic pump tablet did not require laser drilling to deliver the drug to the specific site of action. The tablets were prepared by wet granulation method. The prepared tablets were coated with microporous semipermeable membrane and enteric polymer using conventional pan coating process. The incorporation of sodium lauryl sulfate (SLS), a leachable pore-forming agent, could form in situ delivery pores while coming in contact with gastrointestinal medium. The effect of formulation variables was studied by changing the amounts of sodium alginate and NaCMC in the tablet core, osmogen, and that of pore-forming agent (SLS) used in the semipermeable coating. As the amount of hydrophilic polymers increased, drug release rate prolonged. It was found that drug release was increased as the concentration of osmogen and pore-former was increased. Fourier transform infrared spectroscopy and Differential scanning calorimetry results showed that there was no interaction between drug and polymers. Scanning electron microscopic studies showed the formation of pores after predetermined time of coming in contact with dissolution medium. The formation of pores was dependent on the amount of pore former used in the semipermeable membrane. in vitro results showed acid-resistant, timed release at an almost zero order up to 24 hours. The developed osmotic tablets could be effectively used for prolonged delivery of Diltiazem HCl.
Keywords: Colon-specific delivery, diltiazem HCL, microporous osmotic tablet, semi permeable coating
|How to cite this article:|
Bathool A, Gowda D V, Khan MS, Ahmed A, Vasudha S L, Rohitash K. Development and evaluation of microporous osmotic tablets of diltiazem hydrochloride. J Adv Pharm Technol Res 2012;3:124-9
|How to cite this URL:|
Bathool A, Gowda D V, Khan MS, Ahmed A, Vasudha S L, Rohitash K. Development and evaluation of microporous osmotic tablets of diltiazem hydrochloride. J Adv Pharm Technol Res [serial online] 2012 [cited 2021 Aug 1];3:124-9. Available from: https://www.japtr.org/text.asp?2012/3/2/124/97292
| Introduction|| |
There has been considerable research for design of colonic drug delivery system. Colon targeting can be achieved by several ways, which include prodrugs, pH- and time-dependent systems.  The colon is a site of interest where poorly absorbed drug molecule may have improved bioavailability.  Colon is a reliable site for those drugs where a delay in drug absorption is required from therapeutic point of view, e.g., nocturnal asthma, cardiac arrhythmias, arthritis, which are affected by circadian biorhythms.  Colon is site of interest as it has longer retention time and appears highly responsive to agents that enhance the absorption of poorly absorbed drugs. Colon targeting is usually advised because of various advantages such as reduced dosing frequency, chronotherapy, and delivery of drug to a region that is less hostile metabolically. 
Conventional drug delivery systems have little control over the release of drug and no control over the effective concentration at target site.  Uncontrolled rapid release of drug cause local irritation or systemic toxicity.  By using oral controlled drug delivery, system can provide continuous delivery of drugs at predictable and reproducible kinetics throughout the GI transit. 
Osmotic devices are the most promising devices for the controlled drug delivery. They hold a prominent place because of their reliability and ability to deliver the contents at predetermined zero order rate for prolonged periods.  Osmosis is the noble biophenomenon which is exploited for the delivery of drug in a controlled manner. Osmosis refers to the movement of solvent from region of lower concentration to a region of higher concentration of solute across a semipermeable membrane. 
The osmotic pump tablet is an advanced drug-delivery technique that uses osmotic pressure as driving force for delivery of drug. Osmotic Pump Tablet consists of a core including the drug and osmotic agent, other excipients, and semipermeable membrane coat. , The oral osmotic pump tablet has several advantages such as ease to formulate, simple to operate, reduced side effects, predetermined zero order release of drug, and improved patient compliance, good in vitro-in vivo correlation.  The rate of drug release from osmotic pump is dependent on the total solubility and the osmotic pressure of the core.
Diltiazem hydrochloride (DLZ) is a calcium channel blocker widely used for its peripheral and vasodilator properties. It is used in the management of angina pectoris, cardiac arrhythmia, and hypertension. It has short half-life (3-5 hours), high aqueous solubility with intestine as site of absorption. Hence, development of controlled release formulation is highly desirable, so as to improve therapeutic effects with reduced side effects and improved patient compliance. ,
The aim of the study was to design and characterize microporous osmotic tablet of DLZ for colon-specific delivery which could deliver the drug at constant rate for 24 hours.
| Materials and Methods|| |
DLZ was obtained as a gift sample from Anglo French Drug Company Ltd., Bangalore. Sodium alginate and carboxymethyl cellulose sodium were purchased from Sigma-Aldrich Chemicals, Bangalore. Sodium lauryl sulfate (SLS) and cellulose acetate were obtained from Loba chemie. Eudragit S-100 was obtained from Degussa, Mumbai. Mannitol, magnesium stearate, and PVP K-30 were procured from Glenmark Pharmaceuticals Ltd., Colvale, Goa. Triethyl citrate, isopropyl alcohol, and acetone were procured from Himedia laboratories Pvt. Ltd, Mumbai.
Preparation of tablets
The granules were prepared by wet granulation method. The dry ingredients were passed through sieve #40 and mixed. PVP K-30 (10% w/v) in isopropyl alcohol was used as a binder. The wet mass was passed through sieve #20. The resultant granules were dried at 45 0 C for 4 hours. Dry granules were lubricated with magnesium stearate (1% w/w). The dried granules were then compressed into tablets using 8-mm flat round punches on 10-station rotary tablet machine (Rimek mini press, Mumbai). The average hardness of the compressed tablets was found to be 6.2 ± 0.50 kg/cm 2 while the average thickness was found 2.762 ± 0.298 mm. Formulation chart of prepared tablets are shown in [Table 1].
|Table 1: Formulation table of prepared DLZ tablets with their batch codes|
Click here to view
Coating of the prepared tablets
Three coating solutions of cellulose acetate containing different levels of pore-forming agent SLS (15%w/v, 30%w/v, and 45%w/v) were prepared for semipermeable membrane coating of the tablets. The composition of the coating solutions are given in [Table 2]. Triethyl citrate (2% w/w of total weight of coating materials) was added as plasticizer. The tablets were further coated with an enteric polymer Eudragit S-100. The coating was carried out by a conventional pan coater (Macro Scientific works® New Delhi, India). The rotating speed was kept at 30 rpm for 30 minutes. The coating solution was sprayed with the help of air-less spray gun (Manik Radiators Pvt. Ltd., Mumbai) at a fixed rate of 3 ml/minutes. The coated tablets were dried at 50°C for 4 hours. The average thickness and average weight gain of the tablet after semipermeable coating were found to be 2.965 ± 0.0386 mm and 6.93 ± 0.0502%, respectively. The average thickness and average weight gain of the tablet after enteric coating were found to be 3.426 ± 0.0496 mm and 14.12 ± 0.0526%, respectively.
|Table 2: Composition of coating solutions with varied amount of pore-forming agent|
Click here to view
Characterization of the tablets
Fourier transform infrared spectroscopy
FT-IR analysis was carried out for pure drug and for formulations using KBr pellet method on Fourier transform infrared spectroscopy (FTIR) spectrophotometer type Shimadzu model 8033, USA, in order to ascertain compatibility between drug and polymers used.
Differential scanning calorimetry
All dynamic differential scanning calorimetry (DSC) studies were carried out on DuPont thermal analyzer with 2010 DSC module. The instrument was calibrated using high purity indium metal as standard. The dynamic scans were taken in nitrogen atmosphere at the heating rate of 10°C/minutes.
Scanning electron microscopy
Coated tablets with varying SLS concentration obtained before and after dissolution were examined for their surface morphology by scanning electron microscopy (SEM). The tablets were dried at 50°C for 6 hours and stored b/w sheets of wax paper in dessicator. The samples were coated with gold palladium for 120 seconds and examined under SEM. SEM photographs were taken with a scanning electron microscope Model Joel- LV-5600, USA, at the required magnification at room temperature.
In the case of drug content uniformity test, tablets were pulverized and then transferred into a 250-ml volumetric flask. The volume was adjusted with pH 7.4 phosphate buffer and kept on rotary shaker for 24 hours in order to completely extract the drug. The mixture was filtered, and the drug was assayed spectrophotometrically at 237 nm (Shimadzu UV-1108).
In vitro drug release studies
In vitro drug release studies were performed by using a USP dissolution rate apparatus (apparatus 1, 100 rpm, 37 ± 0.5°C) in pH 1.2 hydrochloric acid buffer (900 ml) for 2 hours as the average gastric emptying time. Then, the dissolution medium was replaced with a pH 7.4 phosphate buffer (900 ml) for rest of the dissolution studies till complete drug release was obtained. The amount of drug released from the tablets at different time intervals was determined spectrophotometrically at 237 nm (Shimadzu UV-1208). All experiments were done in triplicate.
Optimized formulation was selected to assess the stability as per ICH and WHO guidelines. Optimized formulation was sealed in aluminum foil coated inside with polyethylene and kept inside stability chamber maintained at 40°C ± 2 and 75% RH ± 5 for 3 months. The samples were analyzed for drug content, in vitro dissolution, and FTIR spectroscopy at the end of 3 months.
| Results and Discussion|| |
The drug content of the prepared formulation was found to be in range between 48.37 ± 1.17 mg to 49.16 ± 2.13 mg. All batches of prepared tablets show drug content within limits.
Effect of Sodium Alginate and NaCMC
Change in the concentration of sodium alginate and NaCMC in the prepared tablets formulation leads to change in the release pattern of drug. The t 80% values calculated from cumulative drug release vs time plots confirmed the effect of sodium alginate and NaCMC on the release rate of drug from the formulation. Formulation F02C2 showed slower drug release rate (t 80% in 15.311 hours) when compared with other formulations (F01C2 , t 80% in 30 hours) as shown in [Table 3] and [Figure 1]. This is due to fact that in dissolution medium, hydration of sodium alginate and NaCMC takes place leading to swelled gel-like matrix which forms gel layer through which the drug diffusion takes place. These results suggest that appropriate addition of release retardants, especially hydrophilic polymers (Sodium alginate + NaCMC) can control the release of highly water-soluble drug from the osmotic pumps. F03C2, F04C2 releases 80% of the drug within 10 hours, which is not desirable for sustained drug delivery.
|Table 3: Release kinetics, average release rate (t80% values) for the prepared batches of microporous tablets|
Click here to view
|Figure 1: Effect of hydrophilic polymers on the release study of tablets|
Click here to view
Effect of Osmogen
The release studies of different formulations were carried out to assess the effect of osmogen. It was noted that as the amount of osmogen (mannitol) increased, release rate also increased. The formulation F02C2 (t 80% in 15.311 hours) showed slower drug release when compared with F03C2 (t 80% in 9.846 hours) and F04C2 (t 80% in 7.452 hours) shown in [Table 3]. The formulation F01C2 showed undesirable drug release (t 80% in 30 hours) as it contains less amount of osmogen, indicating the development of less osmotic pressure in tablet core.
Effect of Concentration of Pore-forming Agent
Formulation F02C2 showed 80% of drug release in 15 hours and formulation F02C3 showed within 10 hours, while formulation F02C1 showed 76% of drug release up to 24 hours [Table 3], [Figure 2]. Formulation F02C1 showed much slower drug release due to lower concentration of pore-forming agent. The results suggested that 30%w/w of pore-forming agent may be useful to affect optimum release of drug.
|Figure 2: Effect of pore-forming agent on the release study of the optimized formulation|
Click here to view
Scanning Electron Microscopy
Formulations F02C1, F02C2, and F02C3 containing varying concentrations of pore-forming agent (15%, 30%, and 45%w/w) were subjected to SEM studies before and after dissolution as shown in [Figure 3]. Formulations showed non-porous region before dissolution. After dissolution, formulations showed microporous region. SEM study suggested that 30% (w/w) of SLS can be considered as an optimum concentration to obtain maximum release rate without rupturing of the microporous membrane.
|Figure 3: SEM micrographs showing the formation of pores on surface of tablets (a) 15% SLS, (b) 30% SLS, (c) 45% SLS|
Click here to view
Differential Scanning Calorimetry
DSC studies were carried out for DLZ and formulations. DSC thermogram of the DLZ and formulation F02C2 is shown in [Figure 4]. Pure DLZ displayed sharp endothermic peak at 216°C corresponding to the melting point of the drug, and an identical peak was also observed in the tablet formulation. This result clearly indicates that the drug retains its identity in the coated formulation.
|Figure 4: DSC thermograms of pure diltiazem hydrochloride and F02C2 formulation|
Click here to view
Fourier Transform Infrared Spectroscopy
The FTIR spectra of both the pure drug and of tablet formulations showed characteristic peaks at 3433.13/cm (aliphatic C-H stretching), 2931.90/cm (O-CH3, C-H stretching), 2387.93/cm (amine HCl, N-H stretching), 1741.78/cm (acetate C = O stretch), and 773.48/cm (p-substituted aromatic C-H), thus indicating that there was no drug-polymer interaction in the formulation as shown in [Figure 5].
|Figure 5: FTIR spectra of pure diltiazem hydrochloride and F02C2 formulation|
Click here to view
In Vitro Drug Release Studies
Drug release of all prepared tablets was shown in [Figure 1]. It is clearly shown that from all batches of microporous tablets prepared, negligible drug release took place in first 2 hours at pH 1.2. The enteric coating hindered the drug release in stomach. This shows that enteric coating by Eudragit S100 (5% w/v) done was sufficient enough and efficiently prevents the release of drug from tablets at gastric pH 1.2. Drug release started after changing dissolution media pH to 7.4. At pH 7.4, Eudragit S100 enteric coats get dissolved as it is the characteristic of Eudragit S100 to get dissolved above pH 7. Formulation F01C2 releases 20.12 + 1.17%, F02C2 releases 39.78 + 1.32%, F03C2 releases 51.47 + 1.25, F04C2 releases 56.68 + 1.48%, F02C1 releases 6.32 + 1.42, and F02C3 releases 12.48 + 1.35% of drug in 8 hours.
Release kinetics of the tablets prepared is shown in [Table 3]. The best fit model representing the mechanism of drug release from the tablets prepared was of zero order. This is further confirmed by korsmeyer-Peppas model, the value of n is greater than 1 showing case II drug release or anomalous drug release, indicating that two or more mechanism for the drug release are involved, that is diffusion and erosion.
During 3 months of stability studies, formulation was characterized for in vitro drug release, drug content, hardness, and FTIR spectroscopy. The results indicated no significant difference in drug release. The drug content was found to be 48.14 + 0.35. The hardness was also within the limits varying between 6.4 ± 0.23 kg/cm 2 . The FTIR indicated no interaction between drug, and formulation was found to be stable.
| Conclusion|| |
The present study was carried out in order to develop microporous osmotic tablet of DLZ for colon-specific delivery for the treatment of angina pectoris. The preparation of microporous osmotic tablet was simplified by coating the core tablet with an indentation, and the cost was reduced with the elimination of laser drilling. It may be concluded from in vitro study that colon-targeted coated tablets successfully maintained their integrity till the time they reach the colonic fluids. Drug release from the systems followed zero-order kinetics and proved that the system could provide required controlled release rate up to 24 hours.
| References|| |
|1.||Khan MS, Sridhar BK, Srinatha A. Development and evaluation of pH dependent micro beads for colon targeting. Indian J Pharm Sci 2010;72:18-23. |
|2.||Shahidul MI, Jakir A Chowdhury, Monira ST. Study on the development of diltiazem HCl loaded colonic drug delivery systems (CDDS) using various polymers and characterization of their release profiles by in vitro dissolution studies. Dhaka Univ J Pharm Sci 2010;9:7-13. |
|3.||Jose S, Dhanya K, Cinu TA, Aleykutty NA. Multiparticulate system for colon targeted delivery of Ondansetron. Indian J Pharm Sci 2010;72:58-64. |
|4.||Rathbone JM, Jonathan H. Modified release drug delivery technology. 11 th ed. New York: Marcel Dekker Inc; 2002. p. 217-21. |
|5.||Mothilal M, Damodharan N, Lakshmi KS, Sharanya VB, Srikrishna T. Fomulation and in vitro evaluation of osmotic drug delivery system of metoprolol succinate. Int J Pharm and Pharm Sci 2010:2, 64-68. |
|6.||Eckenhoff B, Theeuwes F, Urquhart J. Osmotically activated dosage forms for rate controlled drug delivery. Pharm Technol 1981;5:35-44. |
|7.||Edavalath S, Shivanand K, Kalyani P, Prakash Rao B, Goli D. Formulation development and optimization of controlled porosity osmotic pump tablets of diclofenac sodium. Int J Pharm and Pharm Sci 2011; 3, 80. |
|8.||Meena R, Rahul S, Chelladurai S, Brahmeshwar M. Development and biopharmaceutical evaluation of osmotic pump tablets for controlled delivery of diclofenac sodium. Acta Pharm 2003;53:263-73. |
|9.||Bindschaedler C, Gurny R, Doelker E. Osmotically controlled drug delivery systems produced from organic solutions and aqueous dispersions of cellulose acetate. J Control Release 1986;4:203-12. |
|10.||Hussan KH, Vikram SN, Kumaravelrajan R. Formulation and optimization of aceclofenac monolithic osmotic pump. Int J Pharm Sci Rev Res 2011:6:42-47. |
|11.||Rose S, Nelson JF. A continuous long term injector. Aust J Exp Biol 1955;33:415-20. |
|12.||Pramod K, Sanjay S, Brahmeshwar M. Development and evaluation of elementary osmotic pump of highly water soluble drug: Tramadol hydrochloride. Curr Drug Deliv 2009;6:130-9. |
|13.||Chaffman M, Brogden RN. Diltiazem, a review of its pharmacological properties and therapeutic efficacy. Drugs 1985:29:387-454. |
|14.||Prabu SL, Shirwaikar AA, Shirwaikar A, Ravikumar G, Kumar A, Jacob A. Formulation and evaluation of oral sustained release of diltiazem hydrochloride using rosin as matrix forming material. Ars Pharm 2009;50:32-42. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||Porous Oral Drug Delivery System: Tablets
| ||Shikha Y. Singh,Ruchi Verma,Lalit Kumar |
| ||Pharmaceutical Chemistry Journal. 2018; |
|[Pubmed] | [DOI]|
||A novel enteric positioning osmotic pump capsule-based controlled release system of sinomenine hydrochloride: In vitro and in vivo evaluation
| ||Yulian Sun,Shuangshuang Zhu,Wenjie Lu,Jiayi Chen,Chaojie Sun,Yuxing Guo,Bin Wang,Song Gao,Wenyou Fang,Rongfeng Hu |
| ||Journal of Drug Delivery Science and Technology. 2018; |
|[Pubmed] | [DOI]|
||A simplified stability assessment for selection of a suitable package for microporous osmotic tablets
| ||Su-Hyeon Kim,Jin-Hong Min,Eon-Pyo Hong,Dong-Wook Kim,Eun-Seok Park |
| ||Journal of Drug Delivery Science and Technology. 2017; |
|[Pubmed] | [DOI]|
||A novel co-processed directly compressible release-retarding polymer: Inávitro, solid state and inávivo evaluation
| ||Prashant Kumar Choudhari,H.K. Jain,P. Sharma,B. Srivastava |
| ||Future Journal of Pharmaceutical Sciences. 2017; |
|[Pubmed] | [DOI]|
||The bad taste of medicines: Overview of basic research on bitter taste
| ||Mennella, J.A., Spector, A.C., Reed, D.R., Coldwell, S.E. |
| ||Clinical Therapeutics. 2013; 35(8): 1225-1246 |
||Design and development of controlled porosity osmotic tablet of diltiazem hydrochloride
| ||Shahi, S.R., Zadbuke, N.S., Gulecha, B., Shivanikar, S.S., Shinde, S.B. |
| ||Journal of Advanced Pharmaceutical Technology and Research. 2012; 3(4): 229-236 |